Advertisement

C H Unnikrishnan

Unnikrishnan is currently Senior Associate Editor with BW Businessworld at its Mumbai Bureau. During his two decades long journalistic career, he has received several media awards and recognitions. His articles on healthcare, life sciences and intellectual property rights (IPR) have been republished by several international blogs and journals. 

Latest Articles By C H Unnikrishnan

Saifee Hospital Blames Misled Media For Eman Controversy

C H Unnikrishnan

The unnecessary controversy will certainly impact India’s reputation as a reliable medical tourism destination among global patient community, say the hospital

Read More

‘Can’t Miss India On Our Network’

C H Unnikrishnan

Brussels Airlines sees India as an important market. The airline’s CEO, Bernard Gustin, was in India, soon after the airline brought Mumbai onto its direct route network

Read More

In The Top League

C H Unnikrishnan

In fiscal 2016, Citibank's total assets grew 11 per cent to Rs 154,117 crore, while NPAs remain at 0.44 per cent to advances.

Read More

Chasing ‘Large’ Dreams

C H Unnikrishnan

Since opening its doors in 2004, Yes Bank has become a sizeable bank with total assets rising up to Rs 1,65,263 crore. In fiscal ‘16, advances increased 32.87 per cent, when credit growth has been just about 15 per cent.

Read More

Mylan-Biocon Combine’s Generic Insulin May Hit Market Sooner

C H Unnikrishnan

Insulin glargin is a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar.

Read More

Srei, Vnesheconombank To Set Up $200 Million IT, Innovation Fund

C H Unnikrishnan

Srei Infrastructure Finance has said that it has signed a Memorandum of Understanding with Vnesheconombank, a Russian state development institution which operates to enhance competitiveness of the Russian economy, to create a $200 million IT and Innovation Fund

Read More

India's Patent Office Bans RTI Use By Staffers

C H Unnikrishnan

The IPO circular restricts the officials from accessing information from apex authorities through RTI citing non-access to such information, without availing proper administrative remedy within the office

Read More

Worst Ever Quarter For Indian Pharma

C H Unnikrishnan

Top drug makers such as Sun Pharmaceutical Industries, Dr Reddy’s Laboratories and Cadila Healthcare faced US import ban on their key production facilities in India

Read More

Three Years Of Modi Govt: Healthcare Sector

C H Unnikrishnan

The government announced several good reforms, but without a roadmap or a time frame, they made little difference

Read More

Three Years Of Modi Govt: Crude Challenges

C H Unnikrishnan

Several announcements including consolidation have brought some cheer to the sector. It’s time to execute these goals now

Read More